A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma

European Urology

Volumn 68, Issue 5, 2015, Pages 824-832

  Patschan, Oliver ^a   Sjödahl, Gottfrid ^a   Chebil, Gunilla ^b   Lövgren, Kristina ^b   Lauss, Martin ^b   Gudjonsson, Sigurdur ^a   Kollberg, Petter ^c   Eriksson, Pontus ^b   Aine, Mattias ^b   Månsson, Wiking ^d   Fernö, Mårten ^b   Liedberg, Fredrik ^a   Höglund, Mattias ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c HELSINGBORG HOSPITAL   (Sweden)

^d NONE   (Sweden)

Author keywords

Bladder cancer; High risk; Molecular classification; Outcome; Prognosis; Stage T1

Indexed keywords

P CADHERIN; MESSENGER RNA; TUMOR MARKER;

AGED; ARTICLE; BCG VACCINATION; CANCER GRADING; CANCER RISK; CANCER STAGING; CARCINOMA IN SITU; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; FOLLOW UP; GENE EXPRESSION; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW RISK POPULATION; LYMPH VESSEL METASTASIS; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SEX RATIO; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH; TUMOR VOLUME; BLADDER TUMOR; CLASSIFICATION; COHORT ANALYSIS; DISEASE FREE SURVIVAL; GENETICS; GENOMIC INSTABILITY; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; TUMOR INVASION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENOMIC INSTABILITY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; RNA, MESSENGER; TUMOR BURDEN; URINARY BLADDER NEOPLASMS;

EID: 84942984987     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.02.021     Document Type: Article

References (28)

1. O.R. Faba, J. Palou, A. Breda, and H. Villavicencio High-risk non-muscle invasive bladder cancer: update for a better identification and treatment World J Urol 30 2012 833 840
2. R.J. Sylvester, A.P.M. van der Meijden, W. Oosterlinck, and et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466 477
3. M. Babjuk, W. Oosterlinck, R. Sylvester, and et al. EAU guidelines on non-muscle invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997 1008
4. V. De Marco, M.A. Cerruto, C. D'Elia, and et al. Prognostic role of substaging in T1G3 transitional cell carcinoma of the urinary bladder Mol Clin Oncol 2 2014 575 580
5. B.W. van Rhijn, T.H. van der Kwast, S.S. Alkhateeb, and et al. A new and highly prognostic system to discern T1 bladder cancer substage Eur Urol 61 2012 378 384
6. L. Dyrskjøt, K. Zieger, F.X. Real, and et al. Gene expression signatures predict outcome in non-muscle invasive bladder carcinoma: a multicenter validation study Clin Cancer Res 13 2007 3545 3551
7. R. Kandimalla, A.A. van Tilborg, L.C. Kompier, and et al. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers Eur Urol 61 2012 1245 1256
8. N. Fristrup, K. Birkenkamp-Demtröder, T. Reinert, and et al. Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle invasive bladder cancer Am J Pathol 182 2013 339 349
9. G. Sjödahl, M. Lauss, K. Lövgren, and et al. A molecular taxonomy for urothelial carcinoma Clin Cancer Res 18 2012 3377 3386
10. D. Lindgren, G. Sjödahl, M. Lauss, and et al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma PLoS One 7 2012 e38863
11. G. Sjödahl, K. Lövgren, M. Lauss, and et al. Toward a molecular pathological classification of urothelial carcinoma Am J Pathol 183 2013 681 691
12. A. Orsola, I. Trias, C.X. Raventós, and et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients Eur Urol 48 2005 231 238
13. M.B. Amin, J.K. McKenney, G.P. Paner, and et al. ICUD-EAU International Consultation on Bladder Cancer 2012: pathology Eur Urol 63 2013 16 35
14. C. Busch, and F. Algaba The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems Virchows Arch 441 2002 105 108
15. F. Liedberg, M. Lauss, O. Patschan, and et al. The importance of being grade 3: WHO 1999 versus WHO 2004 pathologic grading Eur Urol 62 2012 620 623
16. W. Choi, S. Porten, S. Kim, and et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy Cancer Cell 25 2014 152 165
17. J.S. Damrauer, K.A. Hoadley, D.D. Chism, and et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology Proc Natl Acad Sci U S A 111 2014 3110 3115
18. The Cancer Genome Atlas Network Comprehensive molecular characterization of urothelial bladder carcinoma Nature 507 2014 315 322
19. D.J. McConkey, W. Choi, and C. Dinney New insights into subtypes of invasive bladder cancer: considerations of the clinician Eur Urol 66 2014 609 610
20. M. Aine, F. Liedberg, G. Sjödahl, and M. Höglund Re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New insights into subtypes of invasive bladder cancer: considerations of the clinician Eur Urol 66 2014 609 610 Eur Urol 2015;67:e73-5
21. J. Fernandez-Gomez, R. Madero, E. Solsona, and et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model J Urol 182 2009 2195 2203
22. M.M. Vedder, M. Márquez, E.W. de Bekker-Grob, and et al. Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours PLoS One 9 2014 e96849
23. J. Galon, A. Costes, F. Sanchez-Cabo, and et al. Type, density, and location of immune cells within human colorectal tumours predict clinical outcome Science 313 2006 1960 1964
24. P. Sharma, Y. Shen, S. Wen, and et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle invasive urothelial carcinoma Proc Natl Acad Sci U S A 104 2007 3967 3972
25. W. Otto, S. Denzinger, W.F. Wieland, and A. Hartmann First analysis of immune cell infiltration in stage pT1 urothelial bladder carcinoma: CD3 positivity as a prognostic marker for cancer-specific survival World J Urol 30 2012 875 877
26. P.K. Lipponen, M.J. Eskelinen, K. Jauhiainen, E. Harju, and R. Terho Tumor infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer Eur J Cancer 29 1992 69 75
27. C. Ayari, H. LaRue, H. Hovington, and et al. High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer Hum Pathol 44 2013 1630 1637
28. B.W. Van Rhijn, L. Liu, A.N. Vis, and et al. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer BJU Int 110 2012 1169 1176